2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups
This article was originally published in Start Up
Executive Summary
Not every acquisition of a venture-backed biotech in 2009 was a structured deal that included earn-outs based on clinical or regulatory milestones. But it sure was close. Thirteen private biotechnology companies were acquired in 2009 and of those deals only a few did not include contingent value rights (CVRs).